|
RIPK1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.87472259938204E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.21059828828152E-11 |
| Normal-vs-Stage2 |
6.15279999999219E-05 |
| Normal-vs-Stage3 |
1.64379621026001E-11 |
| Normal-vs-Stage4 |
8.04067923354523E-12 |
| Stage1-vs-Stage2 |
4.086800E-01 |
| Stage1-vs-Stage3 |
7.745500E-02 |
| Stage1-vs-Stage4 |
1.880360E-02 |
| Stage2-vs-Stage3 |
7.612500E-02 |
| Stage2-vs-Stage4 |
2.189900E-02 |
| Stage3-vs-Stage4 |
3.976000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.21356266649764E-12 |
| Normal-vs-AfricanAmerican |
1.65317999999415E-05 |
| Normal-vs-Asian |
3.15179999987869E-07 |
| Caucasian-vs-AfricanAmerican |
9.134000E-01 |
| Caucasian-vs-Asian |
5.881400E-01 |
| AfricanAmerican-vs-Asian |
6.249400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.13309997127476E-09 |
| Normal-vs-Female |
1.70530256582424E-12 |
| Male-vs-Female |
5.773000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.71720415664822E-11 |
| Normal-vs-Age(41-60Yrs) |
6.20979934140564E-11 |
| Normal-vs-Age(61-80Yrs) |
3.17309956088252E-10 |
| Normal-vs-Age(81-100Yrs) |
5.743600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.270800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.786600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.527600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.839600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.184200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.841400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.105930E-02 |
| Classical-VS-Follicular |
9.841800E-02 |
| Classical-VS-Other |
8.366200E-02 |
| Classical-VS-Normal |
3.4717007046936E-11 |
| Tall-VS-Follicular |
2.496600E-01 |
| Tall-VS-Other |
6.417000E-01 |
| Tall-VS-Normal |
5.13119546852181E-11 |
| Follicular-VS-Other |
4.199400E-01 |
| Follicular-VS-Normal |
7.77599995505085E-09 |
| Other-VS-Normal |
1.800600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.62159960406905E-10 |
| Normal-vs-N1 |
7.8141937365217E-12 |
| N0-vs-N1 |
2.531800E-02 |
|
|
